UCB SA UCB.BR Stock
UCB SA Price Chart
UCB SA UCB.BR Financial and Trading Overview
| UCB SA stock price | 119.85 EUR |
| Previous Close | 108.3 EUR |
| Open | 108 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 107.4 - 108.3 EUR |
| 52 Week Range | 65.4 - 110.15 EUR |
| Volume | 229.82K EUR |
| Avg. Volume | 297.96K EUR |
| Market Cap | 20.43B EUR |
| Beta (5Y Monthly) | 0.378 |
| PE Ratio (TTM) | 60.81921 |
| EPS (TTM) | 1.76 EUR |
| Forward Dividend & Yield | 1.36 (1.26%) |
| Ex-Dividend Date | April 26, 2024 |
| 1y Target Est | 117.7 EUR |
UCB.BR Valuation Measures
| Enterprise Value | 22.66B EUR |
| Trailing P/E | 60.81921 |
| Forward P/E | 16.163664 |
| PEG Ratio (5 yr expected) | 1.1 |
| Price/Sales (ttm) | 3.9423954 |
| Price/Book (mrq) | 2.2759466 |
| Enterprise Value/Revenue | 4.374 |
| Enterprise Value/EBITDA | 17.861 |
Trading Information
UCB SA Stock Price History
| Beta (5Y Monthly) | 0.378 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 110.15 EUR |
| 52 Week Low | 65.4 EUR |
| 50-Day Moving Average | 94.51 EUR |
| 200-Day Moving Average | 81.98 EUR |
UCB.BR Share Statistics
| Avg. Volume (3 month) | 297.96K EUR |
| Avg. Daily Volume (10-Days) | 321.06K EUR |
| Shares Outstanding | 189.78M |
| Float | 120.31M |
| Short Ratio | N/A |
| % Held by Insiders | 36.11% |
| % Held by Institutions | 40.55% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 1.36 |
| Trailing Annual Dividend Yield | 1.25% |
| 5 Year Average Dividend Yield | 154.00% |
| Payout Ratio | 0.7557 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2023 |
| Most Recent Quarter (mrq) | December 31, 2023 |
| Next Fiscal Year End | December 31, 2024 |
Profitability
| Profit Margin | 6.61% |
| Operating Margin (ttm) | 6.19% |
| Gross Margin | 67.05% |
| EBITDA Margin | 24.48% |
Management Effectiveness
| Return on Assets (ttm) | 2.29% |
| Return on Equity (ttm) | 3.80% |
Income Statement
| Revenue (ttm) | 5.18B EUR |
| Revenue Per Share (ttm) | 27.32 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | 1.27B EUR |
| Net Income Avi to Common (ttm) | 343M EUR |
| Diluted EPS (ttm) | 1.77 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 923M EUR |
| Total Cash Per Share (mrq) | 4.86 EUR |
| Total Debt (mrq) | 3.04B EUR |
| Total Debt/Equity (mrq) | 33.85 EUR |
| Current Ratio (mrq) | 1.317 |
| Book Value Per Share (mrq) | 47.299 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 761M EUR |
| Levered Free Cash Flow (ttm) | 311.25M EUR |
Profile of UCB SA
| Country | Belgium |
| State | N/A |
| City | Brussels |
| Address | Allée de la Recherche, 60 |
| ZIP | 1070 |
| Phone | 32 2 559 99 99 |
| Website | https://www.ucb.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 8450 |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Q&A For UCB SA Stock
What is a current UCB.BR stock price?
UCB SA UCB.BR stock price today per share is 119.85 EUR.
How to purchase UCB SA stock?
You can buy UCB.BR shares on the Brussels exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for UCB SA?
The stock symbol or ticker of UCB SA is UCB.BR.
Which industry does the UCB SA company belong to?
The UCB SA industry is Biotechnology.
How many shares does UCB SA have in circulation?
The max supply of UCB SA shares is 191.04M.
What is UCB SA Price to Earnings Ratio (PE Ratio)?
UCB SA PE Ratio is 68.55114000 now.
What was UCB SA earnings per share over the trailing 12 months (TTM)?
UCB SA EPS is 1.76 EUR over the trailing 12 months.
Which sector does the UCB SA company belong to?
The UCB SA sector is Healthcare.
UCB SA UCB.BR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| Nasdaq CRD Global Sustainabilit NQCRD | 1735.62 USD — |
0
|
— — | 1715.94 USD — | 1757.95 USD — | — - | — — |
| BEL 20 BFX | 3850.04 EUR 4208.61 USD |
+0.34
|
— — | — — | — — | — - | — — |
| NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
| Euronext 100 Index N100 | 1521.43 EUR 1663.13 USD |
+0.22
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}